Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome
Clicks: 18
ID: 322497
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
5.1
/100
18 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #30 of 318 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody, improves progression-free survival (PFS) and overall survival in Sézary syndrome (SS). Recently, a multicentre retrospective study conducted by the French Cutaneous Lymphoma study group assessed PFS in 52 patients with SS (median age 73 years, 56% female sex, 75% stage IVA1) who discontinued MOGA for reasons other than disease progression (Moga-stop Study). We report data from an extended follow-up of this cohort, along with comparative PFS outcomes from a parallel SS cohort with continuous MOGA treatment until progression.
| Reference Key |
openalex_W7170137594
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | S. Oro, Florent Amatore, Tarik El Aarbaoui, A de Masson, Anne Pham-Ledard, O. Dereure, Gaëlle Quereux, Sarah Faiz, Marine de Vicq de Cumptich, C Ram-Wolff, R. Janela‐Lapert, Emmanuella Guenova, C. Lheure, Yannick Le Corre, Henri Adamski, Nathalie Bonnet, Florent Grange, L. Troin, S. Tzoumpa, M Bagot, M. Beylot‐Barry |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag211
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.